Brokerages Set uniQure (NASDAQ:QURE) Target Price at $40.00

Shares of uniQure (NASDAQ:QURE) have been assigned an average recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $38.89.

QURE has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $70.00 target price on shares of uniQure in a research report on Tuesday. Leerink Partners increased their price objective on uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a report on Wednesday, December 11th. StockNews.com raised shares of uniQure to a “sell” rating in a report on Wednesday, February 5th. Guggenheim reiterated a “buy” rating on shares of uniQure in a research report on Wednesday, December 11th. Finally, The Goldman Sachs Group raised their price objective on shares of uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 12th.

Insider Activity at uniQure

In other news, CFO Christian Klemt sold 2,916 shares of the stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $11.32, for a total transaction of $33,009.12. Following the completion of the transaction, the chief financial officer now directly owns 155,168 shares of the company’s stock, valued at approximately $1,756,501.76. This represents a 1.84 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Matthew C. Kapusta sold 6,717 shares of uniQure stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total value of $76,036.44. Following the completion of the sale, the chief executive officer now owns 580,795 shares in the company, valued at approximately $6,574,599.40. This trade represents a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 96,044 shares of company stock worth $1,001,040 over the last 90 days. Company insiders own 4.74% of the company’s stock.

Hedge Funds Weigh In On uniQure

A number of large investors have recently made changes to their positions in QURE. Avoro Capital Advisors LLC purchased a new stake in uniQure during the fourth quarter worth about $38,410,000. abrdn plc lifted its position in shares of uniQure by 381.7% during the 3rd quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock valued at $9,510,000 after acquiring an additional 1,528,581 shares during the period. Franklin Resources Inc. purchased a new stake in shares of uniQure during the 3rd quarter worth approximately $7,360,000. RTW Investments LP grew its holdings in shares of uniQure by 8,936.3% in the 4th quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company’s stock worth $15,958,000 after acquiring an additional 893,625 shares during the period. Finally, Point72 Asset Management L.P. increased its stake in uniQure by 81.3% in the 4th quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company’s stock valued at $31,282,000 after purchasing an additional 794,459 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Stock Performance

Shares of QURE stock opened at $12.51 on Friday. uniQure has a 12 month low of $3.73 and a 12 month high of $19.18. The company has a market cap of $609.77 million, a P/E ratio of -2.52 and a beta of 0.38. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The firm has a fifty day moving average price of $14.59 and a 200 day moving average price of $9.92.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.